Patents by Inventor Takao Yoshida

Takao Yoshida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11228217
    Abstract: A bus bar assembly includes bus bars and a bus bar holder that is made of an insulating material and holds the bus bars in a non-contact state. The bus bars include base portions that overlap with other bus bars in the axial direction, and connecting portions extending from the base portions along the radial direction. At least two of the bus bars include stepped portions extending toward the other bus bars between proximal ends of the connecting portions and connection ends connected to windings. The bus bar holder molds the base portions and the stepped portions in a state where the connection ends are exposed.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: January 18, 2022
    Assignee: NIDEC CORPORATION
    Inventors: Yusaku Yoshida, Takao Atarashi, Chiharu Kobayashi, Kentaro Sato
  • Patent number: 11065226
    Abstract: A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: July 20, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takao Yoshida, Akiko Shoyama, Hirotsugu Takano
  • Publication number: 20210198361
    Abstract: The object of the present invention is to provide a method for identifying a patient with malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, and agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on those. The present invention can provide agents for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, characterized by prescriptions based on identifying a patient with a malignant tumor on which the effect of an immune checkpoint inhibitor can be more expected, by analyzing the evaluation items consisting of combinations such as the PD-1 expression intensity, the percentage of the number of PD-1 expressing cells and the like in Treg cells and CD8+ T cells in tumor tissue or blood.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 1, 2021
    Applicants: ONO PHARMACEUTICAL CO., LTD., NATIONAL CANCER CENTER
    Inventors: Hiroyoshi NISHIKAWA, Yosuke TOGASHI, Yukiya OHYAMA, Takao YOSHIDA, Kazuhiko TAKEDA, Kenichi KODA, Atsushi HONDA, Atsushi OYAGI, Toru KAKINUMA, Masayuki MURATA
  • Publication number: 20190255013
    Abstract: A medicament comprising a combination of a compound represented by formula (I), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these and an immune checkpoint inhibitor (such as an anti-PD-1 antibody), which exhibits a strong anti-tumor effect and thus is useful for the treatment of cancer.
    Type: Application
    Filed: July 6, 2017
    Publication date: August 22, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takao YOSHIDA, Akiko SHOYAMA, Hirotsugu TAKANO
  • Patent number: 10289869
    Abstract: A personal information anonymization method is disclosed. Each of a plurality of data including personal information is classified into any one of a plurality of groups based on a degree of commonality of the personal information. An anonymization process, that standardizes the personal information of each of data belonging to each of the groups, is performed for each of the groups. A total number of the data belonging to each of the groups is calculated for each of the groups. The plurality of the groups are classified based on the total number of the sets of the data. A classification result is output.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: May 14, 2019
    Assignee: FUJITSU LIMITED
    Inventors: Masahiro Hamamoto, Shinji Matsune, Takao Yoshida
  • Publication number: 20190048302
    Abstract: The present invention provides a cell culture vessel and a jig for fixing the cell culture vessel in position. More specifically, the cell culture vessel of the present invention is provided with a vessel portion having an annular sealed culture space when viewed from overhead and a port portion connecting the inner portion and outer portion of the culture space. The vessel portion is provided with a first vessel wall serving as the upper side during culturing and a second vessel wall serving as the lower side during culturing. Preferably at least the first vessel wall has flexibility.
    Type: Application
    Filed: February 14, 2017
    Publication date: February 14, 2019
    Applicant: FUKOKU CO., LTD.
    Inventors: Ikumi Suzuki, Takashi Morimura, Takao Yoshida
  • Patent number: 9783609
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 10, 2017
    Assignees: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20170061156
    Abstract: A personal information anonymization method is disclosed. Each of a plurality of data including personal information is classified into any one of a plurality of groups based on a degree of commonality of the personal information. An anonymization process, that standardizes the personal information of each of data belonging to each of the groups, is performed for each of the groups. A total number of the data belonging to each of the groups is calculated for each of the groups. The plurality of the groups are classified based on the total number of the sets of the data. A classification result is output.
    Type: Application
    Filed: July 20, 2016
    Publication date: March 2, 2017
    Inventors: Masahiro Hamamoto, Shinji Matsune, Takao Yoshida
  • Patent number: 9463474
    Abstract: A centrifugal separator separates liquid from solid and includes a hollow bowl and a screw conveyor, the solid discharged from one end of the bowl and the liquid discharged from plural liquid discharge ports at an opposite end of the bowl, the separator further includes a separated liquid jetting device which collects separated liquid that has overflowed the top of an overflow edge of a dam disposed on each discharge port. The separated liquid jetting device has a separated liquid retention chamber that temporarily retains the collected separated liquid inside thereof, a jet nozzle that is open in the direction opposite to the rotation direction of the bowl and that jets out the liquid located inside the separated liquid retention chamber to the outside and the separated liquid jetting device also has a release port formed above the jet nozzle.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: October 11, 2016
    Assignee: TOMOE ENGINEERING CO., LTD.
    Inventors: Takao Yoshida, Masaru Nagasu
  • Publication number: 20150118234
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Applicants: TASUKU HONJO, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
  • Patent number: 8951518
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 10, 2015
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20150011372
    Abstract: Provided is a centrifugal separator equipped with a separated liquid jet nozzle, capable of reducing energy consumption on the rotational drive of a bowl, and capable of avoiding the problem of the solid contained in the raw liquid being discharged through a jet nozzle to a liquid recovery system, and the problem of the adverse effect being produced on the water content ratio in the discharged solid content when the treatment conditions are changed. A separated liquid jetting device 9, which collects the separated liquid that has overflowed the top of an overflow edge 7a of a dam 7, is attached to a front hub 8 at a position on radially outward of each of the liquid discharge ports 6.
    Type: Application
    Filed: October 11, 2013
    Publication date: January 8, 2015
    Applicant: TOMOE ENGINEERING CO., LTD.
    Inventors: Takao Yoshida, Masaru Nagasu
  • Patent number: 8838207
    Abstract: In a radiographic image capturing apparatus, an object to be examined is compressed and secured between a compression plate and an image capturing base, at a position off-center from a central position of the image capturing base near a subject in a direction along the subject. An opening is defined in the compression plate so as to confront the object to be examined in the off-center position. The radiation source irradiates the object to be examined as well as the opening with radiation from a central angle of the radiation source, which is aligned with a vertical axis of the image capturing base, and which passes through the central position from a predetermined angle that is angularly spaced from the central angle about the central position.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: September 16, 2014
    Assignee: FUJIFILM Corporation
    Inventors: Hiroki Nakayama, Hajime Nakata, Naoyuki Okada, Takao Yoshida
  • Patent number: 8815597
    Abstract: The present invention provides a baglike container for centrifugation that is mounted in a centrifuge to thereby allow centrifugation of a dispersion liquid accommodated therein. The baglike container for centrifugation is less likely to tear or break as a result of centrifugation by disposing a container wall surface of the baglike container so as to apply centrifugal force perpendicular to the container wall surface.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: August 26, 2014
    Assignee: Takara Bio Inc.
    Inventors: Hideto Chono, Junichi Mineno, Kazutoh Takesako, Takao Yoshida, Takashi Morimura, Kenji Sakai, Shin-ichi Yamada, Noritsugu Yabe, Yuko Taguchi
  • Publication number: 20130164294
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 27, 2013
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Patent number: 8467495
    Abstract: In a radiographic image capturing apparatus, a biopsy region positional information calculator calculates a three-dimensional position of a biopsy region in an object to be examined based on two radiographic images which are acquired in a stereographic image capturing process, an irradiated field calculator calculates a new irradiated field covering the biopsy region based on the calculated three-dimensional position of the biopsy region and two angles at which a radiation source is disposed in the stereographic image capturing process, and a collimator controller controls a collimator to change the irradiated field of the radiation to the new irradiated field in a next stereographic image capturing process.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: June 18, 2013
    Assignee: Fujifilm Corporation
    Inventors: Naoyuki Okada, Hajime Nakata, Hiroki Nakayama, Takao Yoshida
  • Patent number: 8460886
    Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood, after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: June 11, 2013
    Assignees: Ono Pharmaceutical Co., Ltd., Medarex, Inc.
    Inventors: Shiro Shibayama, Takao Yoshida, Tamon Hayashi, Akio Hayashi, Jun Murai
  • Patent number: 8246955
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: August 21, 2012
    Assignees: Ono Pharmaceutical Co., Ltd., Tasuku Honjo
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • Publication number: 20110280878
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Application
    Filed: June 27, 2011
    Publication date: November 17, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
  • Patent number: 7998479
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: August 16, 2011
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto